Estimations des analystes de Wall Street pour Harvard Bioscience, Inc. (HBIO): objectif de cours de consensus, recommandations achat/conserver/vente et prévisions de revenus, BPA et EBITDA pour les prochains exercices.
Consensus des analystes
| Achat fort | 0 |
| Achat | 4 |
| Conserver | 1 |
| Vente | 0 |
| Vente forte | 0 |
| Analystes au total | 5 |
| Note moyenne (1-5) | 0.80 |
Surprises de Résultats Récentes
| Date | BPA Réel | BPA Estimé | vs Est. |
|---|---|---|---|
| 2026-11-05 | $-0.17 | ||
| 2026-08-11 | $-0.14 | $-0.21 | +33.3% |
| 2026-05-12 | $-0.33 | $-0.62 | +46.8% |
| 2026-03-12 | $-0.64 | $0.04 | -1700.0% |
| 2025-11-06 | $-0.28 | $0.05 | -652.0% |
| 2025-08-11 | $-0.10 | $-0.25 | +60.0% |
| 2025-05-12 | $-0.10 | $-0.20 | +50.0% |
| 2025-03-12 | $0.60 | $0.07 | +757.1% |
Ratios de valorisation
| Prix / Valeur comptable | 4.86 |
| EV / EBITDA | -78.67 |
| Rendement du dividende | 0.00% |
Compte de Résultat (10 ans)
| Année | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenus | $104.5M | $101.9M | $120.8M | $116.2M | $102.1M | $118.9M | $113.3M | $112.2M | $94.1M | $86.5M |
| Coût des Ventes | $56.1M | $54.3M | $57.6M | $51.9M | $44.1M | $51.3M | $52.5M | $46.2M | $39.4M | $40.7M |
| Marge Brute | $48.4M | $47.6M | $63.2M | $64.3M | $58.0M | $67.7M | $60.8M | $66.1M | $54.8M | $45.9M |
| R&D | $5.4M | $5.6M | $11.0M | $10.7M | $8.7M | $10.8M | $12.3M | $11.8M | $10.4M | $8.8M |
| Frais Généraux | $41.4M | $39.6M | $45.8M | $46.0M | $43.4M | $48.9M | $49.5M | $46.9M | $43.7M | $37.0M |
| Charges Opérationnelles | $49.5M | $47.7M | $62.2M | $63.9M | $57.8M | $65.6M | $67.8M | $64.2M | $61.0M | $46.5M |
| Résultat Opérationnel | -$3.0M | -$101000 | $984000 | $377000 | $221000 | $2.1M | -$6.9M | $1.9M | -$6.2M | -$629000 |
| EBITDA | $1.8M | -$101000 | $5.4M | $7.6M | $5.2M | $9.0M | $944000 | $8.0M | -$1.5M | -$46.5M |
| Charges d'Intérêt | $642000 | $713000 | $5.4M | $5.4M | $4.8M | $1.5M | $2.5M | $3.6M | $3.2M | $4.9M |
| Résultat Avant Impôts | -$3.1M | -$2.1M | -$8.5M | -$5.5M | -$7.3M | -$140000 | -$9.2M | -$2.6M | -$11.7M | -$57.4M |
| Impôts | $1.2M | -$1.2M | -$3.7M | -$815000 | $518000 | $148000 | $337000 | $859000 | $740000 | -$686000 |
| Résultat Net | -$4.3M | -$865000 | -$3.5M | -$4.7M | -$7.8M | -$288000 | -$9.5M | -$3.4M | -$12.4M | -$56.7M |
| BPA | $-1.30 | $-0.26 | $-0.97 | $-1.20 | $-2.00 | $-0.07 | $-2.30 | $-0.81 | $-2.80 | $-12.80 |
| BPA Dilué | $-1.30 | $-0.25 | $-0.95 | $-1.20 | $-2.00 | $-0.07 | $-2.30 | $-0.81 | $-2.80 | $-12.80 |
| Actions en Circulation (Diluées) | $3.4M | $3.5M | $3.6M | $3.8M | $3.9M | $4.0M | $4.1M | $4.2M | $4.4M | $4.4M |
Prix
| Prix | $7.97 |
| Capitalisation | $36M |
| Bourse | NASDAQ |
| Pays | US |
Entreprises liées: CLGN · COSM · FEMY · NCNA · NXGL · NXL · RVP
Explorer le secteur: Healthcare · Medical - Instruments & Supplies
Plus de sections de HBIO: Vue d'ensemble · Financiers · Valorisation · Statistiques · Technique · Actionnariat · Actualités · Événements
Découvrir plus: Radar — signaux d'actions sous-évaluées · Académie d'Investissement — apprenez à analyser les actions